Premium
Cyclophosphamide pharmacokinetics in children
Author(s) -
YULE S. M.,
BODDY A. V.,
COLE M.,
PRICE L.,
WYLLIE R.,
TASSO M. J.,
PEARSON A. D. J.,
IDLE J. R.
Publication year - 1996
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1996.tb00153.x
Subject(s) - cyclophosphamide , pharmacokinetics , volume of distribution , pharmacology , medicine , nitrogen mustard , distribution (mathematics) , in vivo , dexamethasone , chemotherapy , biology , mathematical analysis , mathematics , microbiology and biotechnology
1 Cyclophosphamide pharmacokinetics were measured in 38 children with cancer. 2 A high degree of inter‐patient variation was seen in all pharmacokinetic parameters. Cyclophosphamide half‐life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h ‐1 m ‐2 and volume of distribution varied between 0.26 and 1.48 1kg ‐1 . 3 The half–life of cyclophosphamide was prolonged at high dose levels (P = 0.008). 4 Children who had received prior treatment with dexamethasone showed a mean increase in clearance of 2.5 1 h ‐1 m ‐2 ( P = 0.001) presumably as a result of CYP450 enzyme induction. 5 Treatment with allopurinol or chlorpromazine was associated with a significant increase in cyclophosphamide half‐life ( P < 0.001 in both cases). 6 Dose and concurrent treatment may influence cyclophosphamide metabolism in vivo and thus potentially alter the drugs therapeutic effect.